| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | growth hormone | ÇÑ±Û | ¼ºÀåÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀÚ±ØµÇ¸ç ¼Ò¸¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½Ã۸ç ƯÈ÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇÌµÇ¸é ¼ºÀåºÎÁøÀÌ ¿Â´Ù. |
||
| ¿µ¹® | rheumatoid factor | ÇÑ±Û | ·ù¸¶Æ¼½º ÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | IgGÀÇ FcºÎÀ§¿¡ ÀÖ´Â Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼ ÀüÇüÀûÀÎ ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) ȯÀÚÀÇ 80%¿¡¼ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀÚ´Â IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁÖ·Î IgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| ¿µ¹® | sensory nerve | ÇÑ±Û | °¨°¢½Å°æ |
|---|---|---|---|
| ¼³¸í | °¨°¢¼¼Æ÷°¡ ¹ÞÀº ÀÚ±ØÀ» ÁßÃ߽Ű濡 Àü´ÞÇÏ´Â ½Å°æ. ´«À̳ª ÇǺΠµî¿¡ ÀÖ´Â °¨°¢±â°¡ ¿ÜºÎ·ÎºÎÅÍ ÀÚ±ØÀ» ¹ÞÀ¸¸é °¨°¢½Å°æÀ» °ÅÃÄ Ã´¼ö¿Í ´ë³ú°ÑÁú±îÁö °¨°¢ÀÌ Àü´ÞµÈ´Ù. ÀÌ¿Í °°ÀÌ ¿ÜºÎ·ÎºÎÅÍ ³»ºÎ¸¦ ÇâÇØ Àü´ÞµÇ´Â °¨°¢½Å°æÀº ±¸½É¼º ½Å°æ°èÅëÀ̸ç, ¿ø½É¼º ¿îµ¿½Å°æ°èÅë ¹× ÀÚÀ²½Å°æ°èÅë¿¡ ÇÊÀûÇÏ´Â ¸»ÃʽŰæÀÇ ÇϳªÀÌ´Ù. ÀÌ °¨°¢½Å°æ¿¡´Â Èİ¢½Å°æ(³ú½Å°æ¥°)-½Ã°¢½Å°æ(³ú½Å°æ¥±)-´«µ¹¸²½Å°æ(³ú½Å°æ¥²)-»ïÂ÷½Å°æ(³ú½Å°æ¥´)-¾ó±¼½Å°æ(³ú½Å°æ¥¶)-û°¢½Å°æ(³ú½Å°æ¥·)-ÇôÀενŰæ(³ú½Å°æ¥¸)-¹ÌÁֽŰæ(³ú½Å°æ¥¹) ¹× ô¼ö½Å°æÀÌ ÀÖ´Ù. °¨°¢½Å°æ Áß ¹ÌÁֽŰæÀ» Á¦¿ÜÇÏ¸é ¸ðµÎ µÎºÎ¿¡ ºÐÆ÷µÇ¾î ÀÖ°í, Èİ¢½Å°æ-½Ã°¢½Å°æ-û°¢½Å°æÀÇ ¼¼°¡Áö´Â ƯÈ÷ ºÐÈµÈ °¨°¢»óÇǸ¦ Áö¹èÇÑ´Ù. ÇôÀενŰæÀº ¹Ì°¢ÀÇ ¸»´ÜÀåÄ¡¿Í ±× ¹ÛÀÇ ºÎºÐ¿¡ ¿¬°áµÇ°í ¹ÌÁֽŰæÀº Èä°°ú º¹°ÀÇ ±â°ü¿¡ ºÐÆ÷µÇ¾î ±¸½É¼º Ãæ°ÝÀ» ÁßÃß¿¡ Àü´ÞÇÏ¸ç »ïÂ÷½Å°æÀº ô¼öÀÇ °¢ ¸¶µð¿¡ ÀÖ´Â ½Å°æ¿¡ ÇØ´çÇÏ¿©(¸Ó¸®ÀÇ ÇǺÎ-Á¡¸· µîÀÇ Ç¥¸é°¨°¢°ú ½ÉºÎ°¨°¢À» °üÀåÇÑ´Ù. ô¼öÀÇ °¨°¢½Å°æ°èÅë¿¡µµ ÇÇºÎ¿Í ½ÉºÎ, ³»ÀåÀÇ ºÐÆ÷¿¡ µû¸¥ ±¸º°ÀÌ ÀÖ´Ù. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| TGF | T-cell growth factor; transforming growth factor; tuboglomerular feedback; tumor growth factor |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| GRF | gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow... |
| A/S | antiserum |
|---|---|
| HB-EGF | Heparin binding epidermal growth factor-like growth factor |
| HB-EGF | Heparin-binding epidermal growth factor (EGF)-like growth factor |
| NGF | 125)I-nerve growth factor |
| NGF | Anti-nerve growth factor |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| nerve growth factor antiserum | An antiserum containing antibodies against nerve growth factor; when injected into newborn animals the majority of sympathetic ganglion cells are permanently destroyed, resulting in hypoinnervation of peripheral tissues. Synonym: NGF antiserum. (05 Mar 2000) |
|---|
| receptors, nerve growth factor | Cell surface receptors that bind nerve growth factor (ngf) and trigger intracellular changes influencing the behaviour of cells. Nerve growth factor receptors mediate the effects of nerve growth factor on the survival and growth of neurons. (12 Dec 1998) |
|---|---|
| nerve growth factor | <growth factor> A peptide (13.26 kD) of 118 amino acids (usually dimeric) with both chemotropic and chemotrophic properties for sympathetic and sensory neurons. Found in a variety of peripheral tissues, nerve growth factor attracts neurites to the tissues by chemotropism, where they form synapses. The successful neurons are then protected from neuronal death by continuing supplies of nerve growth factor. It is also found at exceptionally high levels in snake venom and male mouse submaxillary salivary glands, from which it is commercially extracted. Nerve growth factor was the first of a family of nerve tropic factors to be discovered. Amino acids 1-81 show homology with proinsulin. Besides its peripheral actions, nerve growth factor selectively enhances the growth of cholinergic neurons that project to the forebrain and that degenerate in Alzheimer's disease. Acronym: NGF (18 Nov 1997) |
| antiserum | <haematology, immunology> Serum containing immunoglobulins against specified antigens. (13 Jan 1998) |
| antiserum anaphylaxis | A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations. Synonym: antiserum anaphylaxis. (05 Mar 2000) |
| monovalent antiserum | See: antiserum. (05 Mar 2000) |
| polyclonal antiserum | A mixture of antibodies to a variety of antigens or to a variety of determinants on a single antigen. (09 Oct 1997) |
| polyvalent antiserum | See: antiserum. (05 Mar 2000) |
| heterologous antiserum | An antiserum that reacts with (e.g., agglutinates) certain microorganisms or other complexes of antigens, even though the antiserum was produced by means of stimulation with a different microorganism or antigenic material. See: homologous antiserum. (05 Mar 2000) |
| homologous antiserum | An antiserum in which there is complete correspondence between the content of antibodies and the antigenic material used for producing the antiserum. (05 Mar 2000) |
| specific antiserum | See: antiserum. (05 Mar 2000) |
| NGF antiserum | An antiserum containing antibodies against nerve growth factor; when injected into newborn animals the majority of sympathetic ganglion cells are permanently destroyed, resulting in hypoinnervation of peripheral tissues. Synonym: NGF antiserum. (05 Mar 2000) |
| brain-derived growth factor | <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3. In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF. In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Acronym: BDGF (12 Dec 1998) |
| vascular endothelial growth factor | A growth factor that is responsible for the growth of blood vessels. (12 Dec 1998) |
| receptors, epidermal growth factor-urogastrone | Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors. (12 Dec 1998) |
| receptors, fibroblast growth factor | Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|